Munich — Scin­to­mics GmbH has sold its stake in Pentix­a­Ph­arm GmbH to Eckert & Zieg­ler Strah­len- und Medi­zin­tech­nik AG. It was advi­sed on the tran­sac­tion by Gütt Olk Feld­haus (GOF). Part of the conside­ra­tion consis­ted of shares in Eckert & Zieg­ler. The parties have agreed not to disc­lose the purchase price.

Pentix­a­Ph­arm is deve­lo­ping a radio­phar­maceu­ti­cal combi­na­tion product against lymphoma and a number of rela­ted tumors that can be used for both the diagno­sis and treat­ment of cancer. In Febru­ary 2021, Pentix­a­Ph­arm had recei­ved confir­ma­tion from the Euro­pean Medi­ci­nes Agency (EMA) that its drug candi­date Pentix­a­For can advance directly into Phase III clini­cal trials.

Scin­to­mics is active in the deve­lo­p­ment, licen­sing and commer­cia­liza­tion of radio-phar­maceu­ti­cal know-how and radio­phar­maceu­ti­cals and was a foun­ding share­hol­der in PentixaPharm.

Eckert & Zieg­ler is a listed company head­quar­te­red in Berlin, Germany, which holds inte­rests in compa­nies in the fields of medi­cal and isotope tech­no­logy as well as radio-phar­macy and nuclear medi­cine, among others.

Legal advi­sors to Scin­to­mics GmbH: Gütt Olk Feld­haus, Munich
Adrian von Prit­t­witz (Part­ner, Lead), Dr. Ricarda Theis (Asso­ciate, both Corporate/M&A)

About Gütt Olk Feldhaus
Gütt Olk Feld­haus is a leading inter­na­tio­nal law firm based in Munich. We provide compre­hen­sive advice on commer­cial and corpo­rate law. Our focus is on corpo­rate law, M&A, private equity and finan­cing. In these specia­list areas we also take on the litigation.